Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza mRNA vaccine MRT5421
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Quadrivalent influenza mRNA vaccine MRT5421 is an investigational messenger RNA-based vaccine developed to provide active immunization against seasonal influenza. It encodes hemagglutinin antigens from four seasonal influenza virus strains, aiming to induce a robust immune response and protection against both type A and B viruses. The vaccine is administered as a single intramuscular injection and is being evaluated for safety and immunogenicity in adults 18 years of age and older. The developer is Sanofi Pasteur, with clinical trials currently in Phase I/II[1][2][8]. The mechanism of action involves the delivery of antigen-encoding mRNA that instructs host cells to produce viral proteins, thereby stimulating an immune response[3][5].
- Other names
- quadrivalent influenza mRNA vaccine MRT5421Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) MRT5421
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent influenza mRNA vaccine MRT5421.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza mRNA vaccine MRT5421.